Researchers investigated the therapeutic potential of the brain-penetrant orally bioavailable, OLIG2 inhibitor CT-179, using Sonic Hedgehog (SHH)- medulloblastoma (MB) explant organoids, patient-derived xenograft, and a genetically-engineered mouse SHH-MB models.
[Nature Communications]